News

Imfinzi is a human monoclonal antibody that binds to PD-L1 and restricts the interaction of PD-L1 with PD-1 and CD80, helping to oppose the tumour’s immune-evading tactics and

Imbruvica is already approved in Europe for chronic lymphocytic leukaemia as a monotherapy or in combination with obinutuzumab in patients who were previously untreated for their condition. The

The new analysis showed that the percentage of patients with complete clearance of all lesions was statistically significantly higher in the VP-102 group than vehicle, across all body

Safety findings from the first cohort were reviewed by the DEC. The Principal Medical Investigator and Sponsor agreed it acceptable to increase the dose of Brilacidin for administration

DRG is engaged in offering high-value data, analytics and insights products and services to the healthcare industry. The deal includes $900m in cash, as well as issuing of

By working with Thermo Fisher to develop Civica-owned Abbreviated New Drug Applications (ANDAs), Civica will secure the manufacture of certain essential medications, further mitigating the risk of drug

NRO-1 is a novel therapeutic with the potential to protect and regenerate corneal nerves in ophthalmic diseases. “Existing treatments for dry eye disease are focused on symptomatic therapy

Via its subsidiary, Merck has completed the cash tender offer to acquire all the outstanding shares of ArQule at a purchase price of $20 per share. Merck said

The FDA has granted the application Priority Review with a Prescription Drug User Fee Act (PDUFA) goal date of May 15, 2020. “The FDA’s acceptance of our application